Home > Oncology > Immunomedics drug Trodelvy extends survival in breast cancer patients

Immunomedics drug Trodelvy extends survival in breast cancer patients

Conference
ESMO 2020
Reuters - 21/09/2020 - Immunomedics Inc's cancer drug Trodelvy, which received accelerated U.S. regulatory approval in April, extended survival time in previously treated patients with an advanced form of breast cancer in a clinical trial, the company said on Saturday. The positive new data could improve Immunomedics' chances of winning full U.S. Food and Drug Administration (FDA) approval for Trodelvy, the lead drug of the Morris Plains, New Jersey-based cancer drugmaker. Immunomedics is being acquired by Gilead Sciences Inc for $21 billion under a deal announced on Sept. 14. The FDA granted the drug accelerated approval for its use in metastatic triple-negative breast cancer (mTNBC) patients who had previously received at least two prior therapies. Its continued approval is contingent upon the FDA's verification of a clinical benefit in confirmatory trials. Trodelvy reduced the risk of death by 52 percent, with a median overall survival of 12.1 months for p...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on